Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Pluri Inc Market Cap
Based on ratings from 0 stock analysts, the Pluri Inc stock price is expected to decrease by 100% in 12 months. This is calculated by using the average 12-month stock price forecast for Pluri Inc. The lowest target is $ and the highest is $. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedPLUR 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Pluri Inc to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on PLUR. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of PLUR.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
Data Not Found! | ||||
When did it IPO
2019
Staff Count
106
Country
Israel
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Yaacov Yanay
Market Cap
$31.1M
In 2023, PLUR generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that PLUR's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 12 Nov 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Pluri Inc. (NASDAQ:PLUR) will hold 1-on-1 meetings and a presentation on November 12, 2024, showcasing its cell-based solutions for multiple industries.
Why It Matters - Pluri Inc.'s 1-on-1 meetings and presentation indicate potential for investor engagement and interest, which may drive stock performance and market perception of the company.
Mon, 11 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - BrainStorm Cell Therapeutics has signed a Memorandum of Understanding with Pluri Inc. to manufacture NurOwn® for a Phase 3b ALS trial, pending a final binding agreement.
Why It Matters - The MOU signals a strategic partnership for manufacturing, potentially accelerating BrainStorm's clinical trial for NurOwn in ALS, which could drive stock value and market confidence.
Thu, 18 Jul 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - PluriCDMO™ is a recognized contract development and manufacturing organization, providing scalable mass production solutions for innovative life science companies.
Why It Matters - PluriCDMO's recognition as a leading partner in scalable production boosts its reputation and potential revenue, indicating strong growth prospects in the life sciences sector.
Tue, 18 Jun 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Pluri Inc. announced a $10 million investment in its subsidiary, Ever After Foods, which focuses on scalable cultivated food technology. Ever After Foods holds exclusive rights to Pluri's technology.
Why It Matters - Pluri Inc.'s investment in Ever After Foods enhances its growth potential in the cultivated meat sector, signaling strong future revenue opportunities and market leadership in sustainable food technology.
Tue, 18 Jun 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Pluri, a biotech firm, has diverse divisions in agtech and foodtech, focusing on cell-based coffee and cultivated meat. Strategic partnerships may enhance value in these sectors.
Why It Matters - Pluri's diverse IP and scalable technology in agtech and foodtech could lead to significant growth. Successful partnerships in cell-based coffee and cultivated meat may enhance value and market position.
Thu, 06 Jun 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Pluri Inc. (Nasdaq:PLUR) has secured a $1.4 million extension from NIAID for year two of its $4.2 million contract to develop PLX-R18 cell therapy for acute radiation syndrome.
Why It Matters - The NIAID's contract extension with Pluri Inc. signals confidence in PLX-R18's potential, enhancing Pluri's revenue prospects and validating its research efforts, which could positively impact stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
